Rich Heyman (ARCH)

Rich Hey­man joins PMV Phar­ma, a p53 biotech, as it adds $70 mil­lion in Se­ries D

Less than a year af­ter pulling in an im­pres­sive $62 mil­lion Se­ries C round, PMV Phar­ma is back at it again.

The Cran­bury, NJ-based biotech an­nounced Mon­day an ad­di­tion­al $70 mil­lion in Se­ries D fi­nanc­ing as it seeks to de­vel­op can­cer ther­a­pies tar­get­ing p53 mu­ta­tions. Ad­di­tion­al­ly, PMV al­so in­tro­duced long­time biotech en­tre­pre­neur Rich Hey­man as chair­man of the board of di­rec­tors.

“This fi­nanc­ing pro­vides PMV Phar­ma with the re­sources to ex­pand our pipeline and to po­ten­tial­ly ad­vance mul­ti­ple p53 ther­a­pies in­to the clin­ic,” said PMV pres­i­dent and CEO David Mack in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.